Association between Attention Deficit Hyperactivity Disorder Medication and Depression: A 10-year Follow-up...

Area of Science:

• Neuroscience
• Psychiatry
• Pediatrics

Background:

• Clinical concern exists regarding methylphenidate (MPH) potentially increasing depression risk in children.
• Attention-deficit/hyperactivity disorder (ADHD) is commonly treated with MPH, necessitating investigation into its side effects.

Purpose of the Study:

• To investigate the association between methylphenidate use and the risk of depression in children and adolescents diagnosed with ADHD.
• To determine if MPH treatment influences the incidence of major depressive disorder (MDD) in a pediatric population.

Main Methods:

• A population-based electronic medical records database was utilized, analyzing claims data from January 2007 to December 2016.
• A self-controlled case series design was employed on 2,330 eligible participants (aged 6-19) diagnosed with ADHD to identify risk factors for MDD.
• Data included ADHD medication prescriptions, depression diagnoses, and antidepressant prescriptions.

Main Results:

• An elevated MDD risk was observed in the 90 days preceding MPH exposure (IRR: 12.12).
• During MPH treatment, the MDD risk significantly increased (IRR: 18.06), returning to baseline after 31 days of discontinuation.
• In younger children (6-9 years), similar patterns of increased MDD risk during MPH treatment were noted.

Conclusions:

• A temporal relationship between depression and methylphenidate use in young people with ADHD is confirmed.
• While the absolute risk of depression is low, it warrants careful consideration, especially during the initial phase of MPH treatment.
• The findings highlight the importance of monitoring for depressive symptoms in pediatric ADHD patients initiating MPH therapy.